Steven B Heymsfield 1, Annaswamy Raji 2, Silvina Gallo 3, Jie Liu 2, Annpey Pong 2, Hakima Hannachi 2, Steven G Terra 4
Main idea: Meaningful reductions in HbA1c, fasting plasma glucose, BW, and SBP were observed with ertugliflozin in patients with overweight and obesity with type 2 diabetes mellitus. Ertugliflozin improved HbA1c and SBP and reduced BW across BMI subgroups. Ertugliflozin was generally well tolerated.
Objective: This study aimed to evaluate ertugliflozin in patients with overweight and obesity with type 2 diabetes mellitus.
Methods: Data from three placebo-controlled, randomized, Phase 3 studies were pooled. Patients with baseline BMI ≥ 25 (1,377/1,544; 89%) were assessed with a stratification by BMI subgroup. Results: At week 26, reductions from baseline in glycated hemoglobin A1c (HbA1c), fasting plasma glucose, body weight ( BW), and systolic blood pressure (SBP) were greater with ertugliflozin versus placebo. Incidence of adverse events was 52.5%, 44.6%, and 50.1% with placebo, ertugslozin 5 mg, 15 mg, and 15 mg compared with placebo. Percent BW changes were similar across BMI subgroups. The study was published in the European Journal of Clinical Pharmacology and Therapeutics.